Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03356054

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse (HOVON 136 NHL)

Phase I-II Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (R-DHAP) in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Stem Cell Transplantation

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland

Conditions DLBCL

Interventions Brentuximab Vedotin R-DHAP

Updated 5 times since 2017 Last updated: Dec 9, 2020 Started: Mar 5, 2018 Primary completion: Jan 31, 2023 Completion: Feb 28, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03356054, this PHASE1/PHASE2 trial focuses on DLBCL and remains actively recruiting participants. Sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland, it has been updated 5 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2018 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Dec 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stichting Hemato-Oncologie voor Volwassenen Nederland

Data source: Stichting Hemato-Oncologie voor Volwassenen Nederland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rotterdam, Netherlands